Stroke
After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH Stroke Scale 0 to 1 at 3 months) at the highest three ALB doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA Stroke Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).
After adjusting for the tPA effect, the probability of good outcome (defined as modified Rankin Scale 0 to 1 or NIH <span class="disease" id="16809570-9-116-122">Stroke</span> Scale 0 to 1 at 3 months) at the highest three <span class="gene" id="16809570-9-170-173">ALB</span> doses was 81% greater than in the lower dose-tiers (relative risk [RR], 1.81; 95% confidence interval [CI], 1.11 to 2.94) and was 95% greater than in the comparable NINDS rt-PA <span class="disease" id="16809570-9-351-357">Stroke</span> Study cohort (RR, 1.95; 95% CI, 1.47 to 2.57).